Latest News and Insights July 2023
Nick McEntee: Getting Clinical Trial Materials Manufacturing Right - Contract Pharma
Nick McEntee, Executive Director, Head of UK GMP Operations at Quotient Sciences discusses strategies for flexible, on-demand manufacture of?clinical trial materials (CTMs) ?with Contract Pharma.
Clinical trials are a critical component in drug development. They require complex and careful planning to be carried out at the highest standards. Manufacturing of clinical trial materials (CTMs), the products used in clinical studies, is one of the key challenges when designing the trials successfully. Read full article here >>
A Day in the Life of a Process Research and Development (PR&D) Chemist
Quotient Sciences’ Alnwick , UK, facility employs over 200 people across a range of scientific disciplines, including process chemistry, solid-state characterization, and radiosynthesis, to support the development and manufacture of?drug substance ?programs at the site. Over the past 2 years, the Alnwick site’s workforce has grown by 20%, which was fueled most recently by the completion of a?major ￡6 million expansion of our drug substance manufacturing facility ?that created an additional 80–100 new scientific and technical jobs. In our latest article, Max Critchlow, a Process Development Chemist on the Drug Substance team at the Alnwick site shares his insight into a typical day of a PR&D chemist at Quotient Sciences. Read more >>
Learn about our drug substance synthesis and manufacturing capabilities
Quotient Sciences provides?drug substance synthesis and manufacturing?capabilities from candidate selection through to commercial production. With our tactical deployment of best-in-class technologies, we minimize chemistry costs and move your drug substance supply off the critical path.
Our streamlined approach to developing drug substances has been shown to reduce manufacturing costs by 50% from pre-clinical to Phase I. To best support our customers' needs, we have made significant investments in technologies and equipment to meet the increasing demand for complex small-scale drug substance manufacturing. Download our latest whitepaper >>
领英推荐
Druggability Technologies (DRGT) Case Study
Druggability Technologies (DRGT)?was a pharmaceutical company developing an array of drugs in diverse indications with the objective of achieving measurable and meaningful improvement in their clinical utility. The company used its proprietary platform to screen and select Super-API compositions and its portfolio contains over 30 preclinical and clinical-stage compounds including?DRGT-46, as a novel therapy for pain. DGRT used integrated services across our network of harmonized development and manufacturing sites in the UK and the US to accelerate drug product development from early phase to scale-up and commercialization. Download now >>
Learn about drug substance and formulation considerations that can help improve downstream clinical outcomes.
Navigating the small molecule CMC pathway from discovery to the clinic comes with its own set of challenges and regulatory hurdles. Once the lead candidate has been selected to move into development, what’s next? With the stakes high, having trusted and experienced guidance at this stage can help streamline the pathway from discovery towards IND, reduce risk and improve the likelihood of clinical success. Consulting group NGT BioPharm Consultants and Quotient Sciences have helped hundreds of customers achieve their IND milestones and beyond. Download now >>
Featured Speakers: